PharmEng Technology is entering the second quarter of 2022 powerfully with a new official entity: PharmEng Nordic ApS. The Anpartsselskab (ApS – the Danish term for private limited company) has its own local office space and talent leadership in Copenhagen, Denmark. This extension of PharmEng marks another step towards a global reach, continuing a great streak of expansions. As a leader of engineering and consulting services in the life sciences, we aim to strengthen our ability to collaborate and serve our clients, globally and locally. PharmEng Nordic ApS can be reached via phone at: +45 9389 1976.
“This expansion will enable PharmEng to connect to our existing customers with presence in the Nordic region, as well as lend our expertise to the emerging world class biotech of Medicon Valley.” – Highlights Dharti Pancholi, Executive Vice President and Global Managing Director at PharmEng. The new territorial reach is thanks to her efforts of business expansion and talent selection.
Dharti Pancholi is also pleased to announce the appointment of new Nordic Managing Director – Steven Davy. Dr. Davy brings his years of experience in the Danish biopharma industry, on top of a wealth of experience from projects across Europe and the USA, and will be making it possible for PharmEng to reach companies and make a difference in the Nordic region.
Opening a formal operation in Denmark continues CEO: Alan Kwong’s withstanding commitment to delivering on his mission statement for over 25 years. The PharmEng mission is to provide unparalleled value to clients to attain regulatory compliance and maintain a competitive advantage in a dynamic regulatory environment under our quality policy.
“The Danish biopharma industry is expanding hugely, together with Scandinavia as a whole. With global offices, PharmEng will be able to supply hugely needed global expertise and local staff experience to the region. The massive expansion of CMOs, APIs and new biotech’s will call upon the GMP and engineering experience PharmEng have inhouse.”
Alan Kwong, Chief Executive Officer of PharmEng Technology
På Dansk
PharmEng Technology starter andet kvartal i 2022 med styrke og etablerer PharmEng Nordic ApS, der ledes fra nyt kontor i København. Med udvidelsen i Danmark tager PharmEng endnu et skridt mod multinational tilstedeværelse. Målet for vores ingeniørfaglige konsulentydelser på life science-området er at understøtte og samarbejde med vores klienter, både lokalt og globalt. PharmEng Nordic ApS kan nås på telefon: +45 9389 1976.
”Udvidelsen vil gøre det muligt for PharmEng at understøtte vores eksisterende kunder i de nordiske lande, ligesom vi åbner for nye samarbejder i Medicon Valley”, understreger Dharti Pancholi, der er Executive Vice President og Global Managing Director i PharmEng. Ekspansionen er på flere måder takket være hendes indsats og store kendskab.
Dharti Pancholi er også glad for at kunne oplyse, at PhD Steven Davy nyligt er tiltrådt som Nordic Managing Director. Steven Davy har mange års erfaring fra dansk biotekindustri, såvel som fra projekter på tværs af USA og Europa. Derfor bliver det nu muligt for PharmEng også at gøre en forskel i de nordiske lande.
Med åbningen af PharmEng Nordic ApS fortsætter Chief Executive Officer Alan Kwong også sit mangeårige løfte. PharmEngs mission er at give værdi til klienter gennem regulatory compliance og derved gøre dem mere konkurrencedygtige.
“The Danish biopharma industry is expanding hugely, together with Scandinavia as a whole. With global offices, PharmEng will be able to supply hugely needed global expertise and local staff experience to the region. The massive expansion of CMOs, APIs and new biotech’s will call upon the GMP and engineering experience PharmEng have inhouse.”
Alan Kwong, Chief Executive Officer of PharmEng Technology